A newly introduced drug approval pathway in the United Kingdom is facing criticism from healthcare experts, who argue that the system may favor pharmaceutical companies more than patients or the public healthcare system. According to an analysis published in The BMJ, the accelerated process could lead to quicker market access for medicines without guaranteeing meaningful benefits for patients.
The pathway was developed to align the review process of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) with evaluations carried out by the National Institute for Health and Care Excellence (NICE). The goal is to allow both agencies to reach decisions on new medicines at roughly the same time, potentially speeding up patient access to treatments.
However, Huseyin Naci of the London School of Economics and Political Science argues that the system creates advantages mainly for the pharmaceutical industry. He explains that the MHRA and NICE assess medicines differently. While the MHRA focuses on safety and clinical effectiveness, NICE evaluates whether a medicine provides better value compared to existing treatments used by the National Health Service (NHS).
According to the commentary, the new pathway does not truly integrate these standards but instead runs two separate evaluations in parallel. This may allow drug manufacturers to begin generating revenue earlier while extending periods during which medicines are exempt from certain rebate mechanisms.
The analysis also warns that accelerated reviews have historically been linked with higher risks of safety concerns emerging after medicines enter the market. Fast-tracked drugs, the author notes, are often associated with more post-marketing safety issues compared to products approved through standard timelines.
Another concern is that NICE committees could be forced to assess medicines using evidence that has not yet been fully reviewed by the MHRA. This could increase uncertainty around decisions involving costly therapies that may later prove less effective or less safe than initially expected.
The commentary further highlights worries about rising healthcare costs. Earlier adoption of expensive medicines with limited added benefit could divert NHS resources away from more cost-effective treatments and healthcare interventions.
Despite the criticism, the author acknowledges that faster access to medicines can be important for patients with serious unmet medical needs. However, he argues that approval systems should prioritize patient outcomes and public health rather than broadly accelerating access for all new medicines regardless of their therapeutic value.
The article concludes with a call for greater transparency from policymakers regarding the expected risks and benefits of the pathway, emphasizing the need to ensure that public healthcare systems remain protected from ineffective, harmful, or overpriced medicines.
